
    Original Text: Previously participated in any other pembrolizumab (MK-3475) study, or received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-Ligand 1 (anti-PD-L1), anti-PD-Ligand 2 (anti-PD-L2), or any other immunomodulating mAb or drug specifically targeting T-cell co-stimulation or checkpoint pathways
    Disease/Condition: Pembrolizumab, Anti-PD-1, Anti-PD-L1, Anti-PD-L2, Immunomodulating mAbs
    Procedure: none
    Drug: none
    Biomarker: none
    Computable Rule: LK MK3475 == True, MK3475 == True, MK3475 == False, MK3475 == False, MK3475 == False, MK3475 == False, MK3475 == False, MK3475 == False, MK347